
样式: 排序: IF: - GO 导出 标记为已读
-
Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-06-21
Background Combating viral hepatitis is part of the UN Sustainable Development Goals (SDGs), and WHO has put forth hepatitis B elimination targets in its Global Health Sector Strategy on Viral Hepatitis (WHO-GHSS) and Interim Guidance for Country Validation of Viral Hepatitis Elimination (WHO Interim Guidance). We estimated the global, regional, and national prevalence of hepatitis B virus (HBV), as
-
New global strategies for HIV, viral hepatitis, and STIs Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-06-17 Udani Samarasekera
Abstract not available
-
Use of cidofovir in recent outbreak of adenovirus-associated acute liver failure in children Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-06-17 Anita Verma, Sunitha Vimalesvaran, Temi Lampejo, Akash Deep, Anil Dhawan
Abstract not available
-
Long-term safety of faecal microbiota transplantation for gastrointestinal diseases in China Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-06-14 Hongliang Tian, Shaoyi Zhang, Huanlong Qin, Ning Li, Qiyi Chen
Abstract not available
-
Food insecurity in the UK: a public health issue left to fester Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-06-13 The Lancet Gastroenterology & Hepatology
Abstract not available
-
Gleaning insight from the PISA trials Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-06-13 Philip James Tozer
Abstract not available
-
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-06-13 Kate P R Dunn, Richard T Oster, Kienan P Williams, Cari E Egan, Angeline Letendre, Harley Crowshoe, Melissa L Potestio, Samuel S Lee
Abstract not available
-
Are all post-ESWL pancreatitis events clinically significant? Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-06-13 Aniruddha Pratap Haripal Singh, Rupjyoti Talukdar, Mohan Ramchandani, Duvvur Nageshwar Reddy
Abstract not available
-
Are all post-ESWL pancreatitis events clinically significant? – Authors' reply Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-06-13 Yang-Yang Qian, Liang-Hao Hu, Zhao-Shen Li, Zhuan Liao
Abstract not available
-
Intestinal microbiota transplantation: do not forget the metabolites Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-06-13 Benjamin H Mullish, Julie A K McDonald, Julian R Marchesi
Abstract not available
-
Promoting the term MAFLD: China in action Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-06-13 Xin-Lei Zhang, Jian-Gao Fan, Lai Wei, Jun-Ping Shi, Ming-Hua Zheng
Abstract not available
-
Hepatitis C in pregnancy and the TiP-HepC registry Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-06-13 Neil Gupta, Lindsey Hiebert, Paige A Armstrong, Carolyn Wester, John W Ward
Abstract not available
-
Correction to Lancet Gastroenterol Hepatol 2022; 7: 511–12 Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-06-13
Abstract not available
-
Correction to Lancet Gastroenterol Hepatol 2022; 7: 617–26 Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-06-13
Abstract not available
-
Research in Brief Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-06-13 Holly Baker
Abstract not available
-
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-23 Edward Kim, Alex Sher, Ghadi Abboud, Myron Schwartz, Marcelo Facciuto, Parissa Tabrizian, Karin Knešaurek, Aaron Fischman, Rahul Patel, Scott Nowakowski, Josep Llovet, Bachir Taouli, Robert Lookstein
Background Unresectable solitary very early to early stage hepatocellular carcinoma is managed with ablation for curative intent. Radiation segmentectomy is a treatment option that delivers radioactive 90yttrium (90Y)-bound microspheres transarterially to a segment of liver. The aim of this study was to assess the safety and efficacy of radiation segmentectomy in patients with unresectable hepatocellular
-
Implementation of radiation segmentectomy for early-stage hepatocellular carcinoma Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-23 Robert J Lewandowski, Riad Salem
Abstract not available
-
Effect of the COVID-19 pandemic on procedure volumes in gastroenterology in the Netherlands Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-21 Milan J Sonneveld, Sander Hardeman, Ernst J Kuipers, Wilmar de Graaf, Manon C W Spaander, Adriaan J van der Meer
Abstract not available
-
Management of gastric varices: still a matter of debate? Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-17 Oana Nicoara-Farcau, Anna Baiges
Abstract not available
-
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-17 Yong Lv, Hui Chen, Bohan Luo, Wei Bai, Kai Li, Zhengyu Wang, Dongdong Xia, Wengang Guo, Qiuhe Wang, Xiaomei Li, Jie Yuan, Hongwei Cai, Jielai Xia, Zhanxin Yin, Daiming Fan, Guohong Han
Background The role of variceal embolisation at the time of transjugular intrahepatic portosystemic shunt (TIPS) creation for the prevention of gastro-oesophageal variceal rebleeding remains controversial. This study aimed to evaluate whether adding variceal embolisation to TIPS placement could reduce the incidence of rebleeding after TIPS in patients with cirrhosis. Methods We did an open-label, randomised
-
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-14 Catharina J Alberts, Gary M Clifford, Damien Georges, Francesco Negro, Olufunmilayo A Lesi, Yvan J-F Hutin, Catherine de Martel
Background Empirical, updated country-level estimates on the proportion of cirrhosis attributable to viral hepatitis are required. We estimated the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in patients with cirrhosis at country, regional, and global levels as an approximation for the fractions of cirrhosis attributable to viral hepatitis. Methods In this systematic
-
Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-14 Petter Brodin, Moshe Arditi
Abstract not available
-
Proportion and stage distribution of screen-detected and non-screen-detected colorectal cancer in nine European countries: an international, population-based study Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-11 Rafael Cardoso, Feng Guo, Thomas Heisser, Harlinde De Schutter, Nancy Van Damme, Mef Christina Nilbert, Anne Julie Tybjerg, Anne-Marie Bouvier, Véronique Bouvier, Guy Launoy, Anne-Sophie Woronoff, Mélanie Cariou, Michel Robaszkiewicz, Patricia Delafosse, Florence Poncet, Paul M Walsh, Carlo Senore, Stefano Rosso, Hermann Brenner
Background The effects of recently implemented colorectal cancer screening programmes in Europe on colorectal cancer mortality will take several years to be fully known. We aimed to analyse the characteristics and parameters of screening programmes, proportions of colorectal cancers detected through screening, and stage distribution in screen-detected and non-screen-detected colorectal cancers to provide
-
Fulfilling the promise of colorectal cancer screening Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-11 Uri Ladabaum
Abstract not available
-
Serrated polyp detection and risk of interval post-colonoscopy colorectal cancer: a population-based study Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-09 David E F W M van Toledo, Joep E G IJspeert, Patrick M M Bossuyt, Arne G C Bleijenberg, Monique E van Leerdam, Manon van der Vlugt, Iris Lansdorp-Vogelaar, Manon C W Spaander, Evelien Dekker
Background Adenoma detection rate (ADR) is a well-established quality indicator for colonoscopy and is inversely associated with the incidence of interval post-colonoscopy colorectal cancer. However, interval post-colonoscopy colorectal cancers frequently develop from serrated polyps, which are not included in the ADR. Therefore, the proximal serrated polyp detection rate (PSPDR) has been proposed
-
Closing the gap for post-colonoscopy colorectal cancer Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-09 Joaquín Cubiella
Abstract not available
-
The problem of antimicrobial resistance in chronic liver disease Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-09 The Lancet Gastroenterology & Hepatology
Abstract not available
-
COVID-19, childhood obesity, and NAFLD: colliding pandemics Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-09 J Bernadette Moore
Abstract not available
-
Closing the gender gap: building a successful career and leadership in research as a female gastroenterologist Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-09 Uma Mahadevan, Neena S Abraham, Anne-Marie Lennon, Aline Charabaty, Séverine Vermeire
Abstract not available
-
Clinical efficacy of endoscopic balloon dilation for Crohn's disease strictures Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-09 Joana Roseira, Maria Manuela Estevinho, Sónia Bernardo, Paula Sousa
Abstract not available
-
Reframing self-expandable metal stents for Crohn's strictures Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-09 Juan Reyes Genere, Parakkal Deepak, Gursimran S Kochhar
Abstract not available
-
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-09 Fangqiang Wei
Abstract not available
-
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma – Authors' reply Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-09 Thomas U Marron, Myron E Schwartz, Elizabeth Miller, Pradeep Thanigaimani, Israel Lowy, Gavin Thurston, Miriam Merad
Abstract not available
-
Comparison of trends in early-onset colorectal cancer in North America and Europe Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-09 Sven Voigtländer, Amir Hakimhashemi, Nina Grundmann, Martin Meyer, Jacqueline Müller-Nordhorn
Abstract not available
-
Comparison of trends in early-onset colorectal cancer in North America and Europe – Authors' reply Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-09 Swati G Patel, Jordan J Karlitz, Timothy Yen, Christopher H Lieu, C Richard Boland
Abstract not available
-
Correction to Lancet Gastroenterol Hepatol 2022; 7: 513–21 Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-09
Abstract not available
-
US FDA recommends transition to disposable duodenoscopes Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-09 Talha Burki
Abstract not available
-
Research in Brief Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-09 Holly Baker
Abstract not available
-
HBV elimination in sub-Saharan Africa: Rwanda's approach to health system integration Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-09 Jean Damascene Makuza, Albert Tuyishime, Naveed Janjua, Neil Gupta
Abstract not available
-
Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-05 Kushala W M Abeysekera, Iain Macpherson, Kate Glyn-Owen, Stuart McPherson, Richard Parker, Rebecca Harris, Andrew Yeoman, Ian A Rowe, John F Dillon
Patients with chronic liver disease are often diagnosed during an index presentation to hospital with decompensated cirrhosis or liver-related events, and these presentations are associated with high mortality. However, there is often a long asymptomatic phase, in which there is an opportunity for earlier diagnosis and interventions to prevent progression to advanced disease. Therefore, strategies
-
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-04-28 Stuart McPherson, Matthew J Armstrong, Jeremy F Cobbold, Lynsey Corless, Quentin M Anstee, Richard J Aspinall, Stephen T Barclay, Paul N Brennan, Tessa M Cacciottolo, Robert D Goldin, Kate Hallsworth, Vanessa Hebditch, Kathryn Jack, Helen Jarvis, Jill Johnson, Wenhao Li, Dina Mansour, Mary McCallum, William Alazawi
Non-alcoholic fatty liver disease (NAFLD) is common, affecting approximately 25% of the general population. The evidence base for the investigation and management of NAFLD is large and growing, but there is currently little practical guidance to support development of services and delivery of care. To address this, we produced a series of evidence-based quality standard recommendations for the management
-
Mystery outbreak of severe acute hepatitis in children Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-04-29 Udani Samarasekera
Abstract not available
-
Nationwide hepatitis C virus screening and treatment of adolescents in Egyptian schools Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-04-28 Ehab Kamal, Noha Asem, Mohamed Hassany, Galal Elshishiney, Wael Abdel-Razek, Heba Said, Sohair Abdel Hamid, Tamer Essam, Ahmed Rehan, Aysam Salah, Tarek Saad, Nasr Shawky, Abdalla Mostafa, Yasser Omar, Islam Ammar, Ramy Saeed, Mohamed AbdAllah, Jean Jabbour, Hala Zaid
Until 2018, Egypt had the highest prevalence of hepatitis C virus (HCV) infection globally, affecting approximately 7% of the population. Despite efforts in diagnosis and treatment since 2006, nearly 2 million individuals with chronic HCV infection had yet to be diagnosed as of early 2018. In December, 2018, a mass HCV screening campaign for adolescents aged 15–18 years was initiated. Among 3 024 325
-
Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-04-27 Ashwin N Ananthakrishnan, Gilaad G Kaplan, Charles N Bernstein, Kristin E Burke, Paul J Lochhead, Alexa N Sasson, Manasi Agrawal, Jimmy Ho Tuan Tiong, Joshua Steinberg, Wolfgang Kruis, Flavio Steinwurz, Vineet Ahuja, Siew C Ng, David T Rubin, Jean-Frederic Colombel, Richard Gearry
Environmental and lifestyle factors play an important role in the natural history of Crohn's disease and ulcerative colitis. A group of international experts from the International Organization for the Study of Inflammatory Bowel Diseases voted on a series of consensus statements to inform the management of inflammatory bowel disease (IBD). The recommendations include avoiding traditional cigarette
-
The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-04-14 Luis Antonio Díaz, Eduardo Fuentes-López, Gustavo Ayares, Francisco Idalsoaga, Jorge Arnold, Andrea Márquez-Lomas, Carolina A Ramírez, María Paz Medel, Francisca Viñuela, Lucas Lacalle, Juan Pablo Roblero, Catterina Ferreccio, Mariana Lazo, Mayur Brahmania, Ashwani K Singal, Melisa Dirchwolf, Nahum Méndez-Sánchez, Norberto Chavez-Tapia, Juan Pablo Arab
Non-alcoholic fatty liver disease (NAFLD) affects 20–25% of the general population and is associated with morbidity, increased mortality, and elevated health-care costs. Most NAFLD risk factors are modifiable and, therefore, potentially amenable to being reduced by public health policies. To date, there is no information about NAFLD-related public health policies in the Americas. In this study, we
-
Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-04-13 Samuel Shribman, Thomas Marjot, Abubakar Sharif, Sunitha Vimalesvaran, Aftab Ala, Graeme Alexander, Anil Dhawan, James Dooley, Godfrey T Gillett, Deirdre Kelly, Alisdair McNeill, Thomas T Warner, Valerie Wheater, William Griffiths, Oliver Bandmann
Wilson's disease is an autosomal-recessive disorder of copper metabolism with hepatic, neurological, psychiatric, ophthalmological, haematological, renal, and rheumatological manifestations. Making a diagnosis can be challenging given that no single test can confirm or exclude the disease, and diagnostic delays are common. Treatment protocols vary and adverse effects, including paradoxical neurological
-
Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-04-12 Elise M Meima-van Praag, Kyra L van Rijn, Karin A T G M Wasmann, Harmanna J Snijder, Jaap Stoker, Geert R D'Haens, Krisztina B Gecse, Michael F Gerhards, Jeroen M Jansen, Marcel G W Dijkgraaf, Jarmila D W van der Bilt, Marco W Mundt, Antonino Spinelli, Silvio Danese, Willem A Bemelman, Christianne J Buskens
Background Guidelines on Crohn's perianal fistulas recommend anti-tumour necrosis factor (TNF) treatment and suggest considering surgical closure for patients with surgically amenable disease. However, long-term outcomes following these two strategies have not been directly compared. The aim of this study was to assess radiological healing in patients who received short-term anti-TNF treatment and
-
Psychobiotics: feeding the gut to nurture the brain. Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-01 Kirsten Berding,Heidi M Staudacher
-
Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-01 Tommaso Lorenzo Parigi,Ferdinando D'Amico,Maria T Abreu,David T Rubin,Axel Dignass,Iris Dotan,Vipul Jairath,Fernando Magro,Laurent Peyrin-Biroulet,Subrata Ghosh,Silvio Danese
-
Inequities in alcohol-related harm in the Philippines. Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-01 Isabelle Rose I Alberto,Nicole Rose I Alberto,Michelle Ann B Eala,Maria Katrina M Mata,Jasper Seth Yao
-
The costs of inadequate toilet coverage in the Philippines. Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-01 Janine Patricia G Robredo,Michelle Ann B Eala,Norman Dennis E Marquez,Romelei Camiling-Alfonso
-
Opacity over live vaccines in infants exposed to infliximab. Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-05-01 The Lancet Gastroenterology Hepatology
-
Global epidemiology and prevention of colorectal cancer Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-04-07 Mingyang Song
Abstract not available
-
Correction to Lancet Gastroenterol Hepatol 2022; 5: 426–45 Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-04-07
Abstract not available
-
Global epidemiology and prevention of colorectal cancer. Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-04-07 Mingyang Song
-
Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-04-07
Background Colorectal cancer is the third leading cause of cancer deaths worldwide. Given the recent increasing trends in colorectal cancer incidence globally, up-to-date information on the colorectal cancer burden could guide screening, early detection, and treatment strategies, and help effectively allocate resources. We examined the temporal patterns of the global, regional, and national burden
-
Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-04-06 Judith Wellens, Stephanie Brann, Alex Adams, Luke Marlow, James O Lindsay, Jack J Satsangi
Abstract not available
-
Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease. Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-04-06 Judith Wellens,Stephanie Brann,Alex Adams,Luke Marlow,James O Lindsay,Jack J Satsangi
-
The role of mucins in gastrointestinal barrier function during health and disease Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-04-06 Tom Breugelmans, Baptiste Oosterlinck, Wout Arras, Hannah Ceuleers, Joris De Man, Georgina L Hold, Benedicte Y De Winter, Annemieke Smet
Mucins are the gatekeepers of the mucosal barrier of the gastrointestinal tract and are aberrantly expressed in various gastrointestinal pathologies, including pathogen infection, inflammation, and uncontrolled growth and spread of abnormal cells. Although several studies have emphasised the role of mucins in dysfunction of the gastrointestinal mucosal barrier, they are often still considered to be
-
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study Gastroenterol. Hepatol. (IF 18.486) Pub Date : 2022-03-30 Katsuyoshi Matsuoka, Mamoru Watanabe, Toshihide Ohmori, Koichi Nakajima, Tetsuya Ishida, Yoh Ishiguro, Kazunari Kanke, Kiyonori Kobayashi, Fumihito Hirai, Kenji Watanabe, Hidehiro Mizusawa, Shuji Kishida, Yoshiharu Miura, Akira Ohta, Toshifumi Kajioka, Toshifumi Hibi
Background AJM300 is an oral, small-molecule α4-integrin antagonist. We assessed the efficacy and safety of AJM300 in patients with moderately active ulcerative colitis. Methods This multicentre, randomised, double-blind, placebo-controlled, phase 3 study consisted of two phases: a treatment phase and an open-label re-treatment phase. The study was done at 82 hospitals and clinics in Japan. Patients